TriangleNCT01919619 · OUTCOME
Progression-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 36 months
What was measured
Number of participants that are alive and disease free 36 months long post transplant
Groups in this outcome
Autologous -Treatment (Lenalidomide and Ipilimumab)
Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
Allogeneic - Treatment (Lenalidomide and Ipilimumab)
Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
| Group | Source count |
|---|---|
| Autologous -Treatment (Lenalidomide and Ipilimumab) | 28 |
| Allogeneic - Treatment (Lenalidomide and Ipilimumab) | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Autologous -Treatment (Lenalidomide and Ipilimumab) | 18 | Not reported | Not reported | Not reported | Not reported |
| Allogeneic - Treatment (Lenalidomide and Ipilimumab) | 4 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 28
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- Number of participants that are alive and disease free 36 months long post transplant
- groups
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- OG000
- title
- Autologous -Treatment (Lenalidomide and Ipilimumab)
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- OG001
- title
- Allogeneic - Treatment (Lenalidomide and Ipilimumab)
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Up to 36 months
- title
- Progression-free Survival
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice